Physician profile
Michael R Rupp
NPI 1568414985
$40,613.02
in general payments reported to CMS, 2019-2025
28 companies · $37K in 2025
The $37K reported for 2025 was more than what 95% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $511 · 2020: $337 · 2021: $610 · 2022: $726 · 2023: $869 · 2024: $860 · 2025: $37K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $34K · Food and Beverage: $3,493 · Travel and Lodging: $885 · Education: $162 · Consulting Fee: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $33,800.00 |
| Food and Beverage | $3,493.24 |
| Travel and Lodging | $885.14 |
| Education | $161.77 |
| Consulting Fee | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $36,095.89 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $1,310.87 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Csl Behring | $667.14 | 2019-2025 | Hizentra, Privigen, Haegarda |
| Regeneron Healthcare Solutions, INC. | $305.22 | 2019-2025 | Dupixent |
| Ars Pharmaceuticals Operations, INC. | $263.41 | 2025 | Neffy |
| Genzyme Corporation | $247.66 | 2019-2025 | |
| Grifols USA, LLC | $223.52 | 2021-2025 | Xembify, Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $213.48 | 2020-2025 | Cuvitru, Hyqvia |
| Pfizer INC. | $174.36 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $138.20 | 2022-2025 | |
| Horizon Therapeutics Plc | $123.69 | 2022 | |
| Alk-Abello, INC | $123.26 | 2019 | |
| Incyte Corporation | $123.01 | 2021-2025 | Opzelura |
| Optinose US, INC. | $116.64 | 2019-2023 | |
| Blueprint Medicines Corporation | $96.28 | 2023-2025 | Ayvakit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $82.65 | 2024-2025 | Ruconest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.11 | 2020-2021 | |
| Verona Pharma, INC. | $37.97 | 2025 | Ohtuvayre |
| Amgen INC. | $34.00 | 2025 | |
| Viatris Specialty LLC | $29.48 | 2025 | Yupelri |
| Genentech USA, INC. | $20.82 | 2024 | Xolair |
| Galderma Laboratories, L.P. | $18.06 | 2025 | Nemluvio |
| Biocryst US Sales Co., LLC | $17.37 | 2021 | |
| Lilly USA, LLC | $16.54 | 2025 | Ebglyss |
| Merck Sharp & Dohme LLC | $15.36 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.84 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $14.19 | 2021 | |
| Adma Biomanufacturing LLC | $13.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rupp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.